Relative contribution of HIV infection, demographics and body mass index to bone mineral density

AIDS

Volumn 28, Issue 14, 2014, Pages 2051-2060

  Cotter, Aoife G ^a,b   Sabin, Caroline A ^c   Simelane, Sibongile ^a   Macken, Alan ^a   Kavanagh, Eoin ^d   Brady, Jennifer J ^d   McCarthy, Geraldine ^b   Compston, Juliet ^e   Mallon, Patrick W G ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Department of Radiology ^*  (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

BMI; Bone disease; Bone mineral density; Bone turnover; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AFRICAN; ARTICLE; BODY MASS; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; DEMOGRAPHY; DRUG EXPOSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HETEROSEXUALITY; HIP; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIFESTYLE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; COHORT ANALYSIS; COMORBIDITY; COMPLICATION; CROSS-SECTIONAL STUDY; HIV INFECTIONS; LUMBAR VERTEBRA; MIDDLE AGED; OSTEOPOROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PROSPECTIVE STUDY; RISK FACTOR; UNITED KINGDOM; VIRUS LOAD;

ABSORPTIOMETRY, PHOTON; ADULT; BODY MASS INDEX; BONE DENSITY; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; FEMUR NECK; GREAT BRITAIN; HIP; HIV INFECTIONS; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 84906761468     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000353     Document Type: Article

References (31)

1. Bhavan KP, Kampalath VN, Overton ET. The aging of the HIV epidemic. Curr HIV/AIDS Rep 2008; 5: 150-158.
2. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21: 617-623.
3. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE. HIV infection and bone mineral density in middle-Aged women. Clin Infect Dis 2006; 42: 1014-1020.
4. Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004; 89: 1200-1206.
5. Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200: 1746-1754.
6. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22: 395-402.
7. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004; 18: 475-483.
8. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006; 91: 2938-2945.
9. Yin MT, McMahon DJ, Ferris DC, Zhang CA, Shu A, Staron R, et al. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2010; 95: 620-629.
10. Sharma A, Flom PL, Weedon J, Klein RS. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 2010; 24: 2337-2345.
11. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-Analytic review. AIDS 2006; 20: 2165-2174.
12. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51: 963-972.
13. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis 2011; 203: 1791-1801.
14. Martin A, Moore C, Mallon P W, Hoy J, Emery S, Belloso W, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS 2013; 27: 2403-2411.
15. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23: 817-824.
16. Bolland MJ, Grey AB, Gamble GD, Reid IR. CLINICAL Review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-Analysis. J Clin Endocrinol Metab 2007; 92: 4522-4528.
17. Szulc P. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clin Biochem 2012; 45: 907-919.
18. Szulc P, Montella A, Delmas PD. High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study. Ann Rheum Dis 2008; 67: 1249-1255.
19. Szulc P. Biochemical bone turnover markers and osteoporosis in older men: where are we? J Osteoporos 2011; 2011: 704015.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Inter Med 1999; 130: 461-470.
21. Cotter AG, MallonPW. The effects of untreated and treated HIV infection on bone disease. Curr Opin HIV AIDS 2014; 9: 17-26.
22. Grijsen ML, Vrouenraets SM, Steingrover R, Lips P, Reiss P, Wit FW, Prins JM. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS 2010; 24: 2233-2238.
23. Grijsen ML, Vrouenraets SM, Wit FW, Stolte IG, Prins M, Lips P, et al. Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis 2013; 207: 386-391.
24. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93: 3499-3504.
25. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Obel N. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS 2012; 26: 285-293.
26. Guerri-Fernandez R, Vestergaard P, Carbonell C, Knobel H, Aviles FF, Castro AS, et al. HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. J Bone Miner Res 2013; 28: 1259-1263.
27. FitzGerald G, Boonen S, Compston JE, Pfeilschifter J, LaCroix AZ, Hosmer DW Jr, et al. Differing risk profiles for individual fracture sites: evidence from the Global Longitudinal Study of Osteoporosis in Women (GLOW). J Bone Miner Res 2012; 27: 1907-1915.
28. Cotter AG, Vrouenraets SM, Brady JJ, Wit FW, Fux CA, Furrer H, et al. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients: a substudy of the PREPARE Study. J Clin Endocrinol Metab 2013; 98: 1659-1666.
29. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
30. van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23: 1367-1376.
31. Tinago W, O'Halloran J, O'Halloran R, Macken A, Lambert J, Sheehan G, Mallon P. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions. HIV medicine 2014; 15: 224-232.